ASX Announcement

13th August 2025

ANOTHER FIRST; VITASORA UNLOCKS US$4M+ MEDICAID OPPORTUNITY WITH TAMPA FAMILY HEALTH CENTERS 48,000 PATIENTS

Highlights

- Vitasora expands existing partnership with Tampa Family Health Centers (TFHC) to now include Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services for Medicaid patients
- TFHC is **Florida's largest** Federally Qualified Health Center (FQHC), serving **~48,000** Medicaid patients across 23 clinical locations
- First FQHC in Florida to deliver Vitasora's value-based care programs to underserved communities
- Estimated **7,000+ Medicaid patients** to be enrolled, generating **~US$4+ million** in annualised revenue
- Fee-For-Service rates range from **US$35–US$90** per patient per month, depending on the service levels
- Expansion builds on Vitasora's proven care outcomes and TFHC's mission of delivering healthcare equity

---

Vitasora Health Limited (ASX:VHL; OTCQB:VHLUF) ("Vitasora" or "the Company"), a leader in the delivery of AI-powered, Connected Care solutions in the U.S. healthcare market, is pleased to announce an expansion of its existing agreement with Tampa Family Health Centers (TFHC) to now include Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services for Medicaid-covered patients.

TFHC is the largest Federally Qualified Health Center (FQHC) in Florida, operating more than 23 clinics across Hillsborough County and serving more than **114,000 patients** and 42%[1], or approximately **48,000 Medicaid beneficiaries.** Its mission is to provide high-quality, accessible care to all individuals, regardless of income or insurance status.

1. https://www.chcchronicles.org/explore/tampa-family-health-centers-inc

This expanded agreement marks a first in Florida for FQHCs, bringing Vitasora's connected care model to underserved populations, many of whom face complex chronic conditions that often go unmanaged. The collaboration highlights both organizations' shared commitment to health equity and closing care gaps for vulnerable patient groups. This expanded scope of work is a testament to the successful roll out of the existing Medicare CCM program. This proposed, jointly developed unique approach for the Medicaid program further builds on this foundation, aiming to deliver even greater value and improved outcomes for the communities we serve.

Of the ~40,000 Medicaid patients TFHC currently serves, it is estimated that approximately 20,000 are eligible for CCM and RPM services under current CMS guidelines. With an estimated 30% enrolment rate, approximately 7,000 patients are expected to participate in the program, generating ~US$4+ million in annualised revenues. Fee-For-Service rates will range from US$35 to US$90 per patient per month, depending on the level of care provided.

The contract is for an initial term of one year, with an automatic 12-month renewal unless either party provides notice of termination. The agreement includes a standard 90-day no-fault termination clause.

The program is expected to be execution-ready within 30 days, with the first Medicaid patients enrolled from mid- September 2025. Initial revenues are anticipated to begin flowing 30 to 60 days thereafter, aligning with CMS reimbursement cycles.

While reimbursement for Medicaid patients is typically lower than for Medicare, TFHC and Vitasora are aligned on a long-term vision: to prioritise access, quality and continuity of care.

There is significant interest in this Vitasora/Tampa patient initiative. With approximately 1,400 FQHCs nationwide, serving over 32 million patients, many of whom are covered by Medicaid and Medicare; scalability of this Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services presents a substantial opportunity to improve care delivery for underserved populations. This aligns directly with the mission of FQHCs to promote equity of care by providing high-quality services to those who need it most. As FQHCs seek innovative solutions to enhance patient outcomes and meet the growing demands of their communities, this represents a multi-billion-dollar market with the potential to drive real, systemic change in healthcare delivery across the U.S.

Vitasora CEO, Marjan Mikel, said: *"We are proud to expand our partnership with Tampa Family Health Centers, a nationally respected leader in community healthcare. This initiative reflects our shared belief that high-quality, digitally enabled care should be accessible to all Americans. It's a significant step forward in delivering real, universal impact at scale. Together, our partnership demonstrates the power of effective, equitable value-based healthcare."*

This Medicaid program with TFHC is a critical pillar in Vitasora's broader U.S. strategy to expand access to value-based care across both Medicare and Medicaid populations. It builds on the success of the Company's Medicare Shared Savings Program (MSSP) contracts and positions Vitasora as a first-mover in underserved care innovation.

The Company continues to engage with other healthcare organisations across the country to replicate similar models and expects to announce further agreements in due course.

For further information, investors and media please contact:

Mr Marjan Mikel

CEO & Managing Director

Vitasora Health Limited

P: +61 408 462 873

E: marjan@vitasorahealth.com

Mr Nicholas Smedley

Non-Executive Chairman

Vitasora Health Limited

P: +61 447 074 160

E: nicholas@vitasorahealth.com

This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.

About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:RSHUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.vitasorahealth.com.au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit https://respiri.co/us/ or for wheezo®

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.